Annual report pursuant to Section 13 and 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)

v3.7.0.1
SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2016
Sep. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Jun. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Collaborative arrangement              
Collaborations              
Maximum amount of contingent payments receivable       $ 531,900,000   $ 531,900,000  
BerGenBio A S Worldwide License Agreement              
Collaborations              
Upfront fee received $ 1,700,000            
Revenue recognized         $ 3,700,000    
Payment received from exercise of option rights $ 2,000,000            
Specified Development Events | Collaborative arrangement              
Collaborations              
Maximum amount of contingent payments receivable       148,800,000   148,800,000  
Specified Regulatory Events | Collaborative arrangement              
Collaborations              
Maximum amount of contingent payments receivable       345,600,000   345,600,000  
Specified Product Launch Events | Collaborative arrangement              
Collaborations              
Maximum amount of contingent payments receivable       37,500,000   37,500,000  
Bristol-Myers Squibb Company              
Collaborations              
Upfront fee received     $ 30,000,000        
Contingent payments             $ 309,000,000
Deferred revenue related to upfront payment     $ 30,000,000        
Revenue recognized       $ 3,000,000   13,400,000 16,600,000
Bristol-Myers Squibb Company | Research Activities              
Collaborations              
Revenue recognized           $ 290,000 822,000
Aclaris              
Collaborations              
Upfront fee received   $ 8,000,000          
Contingent payments             80,000,000
Revenue recognized             $ 8,000,000